Pomalidomide (BioDeep_00000182548)
human metabolite blood metabolite Chemicals and Drugs
代谢物信息卡片
4-amino-2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione
化学式: C13H11N3O4 (273.0749526)
中文名称: 泊马度胺
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N
InChI: InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)
描述信息
C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent > C157388 - Immunomodulatory Imide Drug
L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants
D006133 - Growth Substances > D043924 - Angiogenesis Modulating Agents
D000970 - Antineoplastic Agents > D020533 - Angiogenesis Inhibitors
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor
D006133 - Growth Substances > D006131 - Growth Inhibitors
D007155 - Immunologic Factors
同义名列表
12 个代谢物同义名
4-amino-2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione; 4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione; 3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide; S-3-amino-phthalimido-Glutarimide; 3-aminio-phthalimido-Glutarimide; 3-Aminophthalimidoglutarimide; 4-Aminothalidomide; Pomalidomide; Pomalyst; CC 4047; CC-4047; S-3APG
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:72690
- PubChem: 134780
- HMDB: HMDB0256694
- DrugBank: DB08910
- ChEMBL: CHEMBL43452
- Wikipedia: Pomalidomide
- chemspider: 118785
- CAS: 19171-19-8
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Ya-Ni Huang, Nigel H Greig, Pen-Sen Huang, Yung-Hsiao Chiang, Alan Hoffer, Chih-Hao Yang, David Tweedie, Ying Chen, Ju-Chi Ou, Jia-Yi Wang. Pomalidomide Improves Motor Behavioral Deficits and Protects Cerebral Cortex and Striatum Against Neurodegeneration Through a Reduction of Oxidative/Nitrosative Damages and Neuroinflammation After Traumatic Brain Injury.
Cell transplantation.
2024 Jan; 33(?):9636897241237049. doi:
10.1177/09636897241237049. [PMID: 38483119] - Haimin Chen, Haiqi Chen, Yan Zhou, Weiwei Xu, Jingjing Yu, Yao Xu, Fan Zhou. Comparative efficacy of novel-drugs combined therapeutic regimens on relapsed/refractory multiple myeloma: a network meta-analysis.
Hematology (Amsterdam, Netherlands).
2023 Dec; 28(1):2225342. doi:
10.1080/16078454.2023.2225342. [PMID: 37343159] - Liquan Zhu, Shiqi Hu, Xiaoqiao Yan, Qian Zeng, Bei Zhang, Linye Jiang, Shao Q Yao, Jingyan Ge. Ugi reaction-assisted assembly of covalent PROTACs against glutathione peroxidase 4.
Bioorganic chemistry.
2023 05; 134(?):106461. doi:
10.1016/j.bioorg.2023.106461. [PMID: 36924654] - Qi Zhang, Peizheng Yan, Pan Zhao, Dongsheng Zhao, Heran Cao, Jing Lu, Beibei Mao. Design, Synthesis, and Biological Evaluation of mTOR-Targeting PROTACs Based on MLN0128 and Pomalidomide.
Chemical & pharmaceutical bulletin.
2023 Feb; 71(2):120-128. doi:
10.1248/cpb.c22-00576. [PMID: 36436947] - Yating Li, Jiamei Ji, Hua Lu, Jianyong Li, Xiaoyan Qu. Pomalidomide-based therapy for extramedullary multiple myeloma.
Hematology (Amsterdam, Netherlands).
2022 Dec; 27(1):88-94. doi:
10.1080/16078454.2021.2019364. [PMID: 35068387] - Faouzi Djebbari, Alexandros Rampotas, Grant Vallance, Fotios Panitsas, Nanda Basker, Gina Sangha, Beena Salhan, Farheen Karim, Al-Kaisi Firas, Amy Gudger, Loretta Ngu, Matt Poynton, Ho Pui Jeff Lam, Lowri Morgan, Laura Yang, Jennifer Young, Mairi Walker, Ismini Tsagkaraki, Laura Anderson, Saleena Rani Chauhan, Rebecca Maddams, Richard Soutar, Margarita Triantafillou, Steve Prideaux, Abubaker Obeidalla, Toby A Eyre, Ceri Bygrave, Supratik Basu, Karthik Ramasamy. Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study.
Hematology (Amsterdam, Netherlands).
2022 Dec; 27(1):691-699. doi:
10.1080/16078454.2022.2082725. [PMID: 35666686] - Fatiha Rachedi, Kimiko Koiwai, Nadia Gaudel-Dedieu, Bernard Sebastien, Hoai-Thu Thai, Claire Brillac, Jean Baptiste Fau, Laurent Nguyen, Helgi van de Velde, Christine Veyrat-Follet, Dorothée Semiond. Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.
CPT: pharmacometrics & systems pharmacology.
2022 Jun; 11(6):766-777. doi:
10.1002/psp4.12789. [PMID: 35355430] - Nizar J Bahlis, David S Siegel, Gary J Schiller, Christy Samaras, Michael Sebag, Jesus Berdeja, Siddhartha Ganguly, Jeffrey Matous, Kevin Song, Christopher S Seet, Mirelis Acosta-Rivera, Michael Bar, Donald Quick, Bertrand Anz, Gustavo Fonseca, Weiyuan Chung, Kim Lee, Jorge Mouro, Amit Agarwal, Donna Reece. Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial.
Leukemia & lymphoma.
2022 06; 63(6):1407-1417. doi:
10.1080/10428194.2022.2030477. [PMID: 35133221] - Hoai-Thu Thai, Nadia Gaudel, Marc Cerou, Geraldine Ayral, Jean-Baptiste Fau, Bernard Sebastien, Helgi van de Velde, Dorothée Semiond, Christine Veyrat-Follet. Joint modelling and simulation of M-protein dynamics and progression-free survival for alternative isatuximab dosing with pomalidomide/dexamethasone.
British journal of clinical pharmacology.
2022 05; 88(5):2052-2064. doi:
10.1111/bcp.15123. [PMID: 34705283] - Fredrik H Schjesvold, Meletios-Athanasios Dimopoulos, Sosana Delimpasi, Pawel Robak, Daniel Coriu, Wojciech Legiec, Luděk Pour, Ivan Špička, Tamas Masszi, Vadim Doronin, Jiri Minarik, Galina Salogub, Yulia Alekseeva, Antonio Lazzaro, Vladimir Maisnar, Gábor Mikala, Laura Rosiñol, Anna Marina Liberati, Argiris Symeonidis, Victoria Moody, Marcus Thuresson, Catriona Byrne, Johan Harmenberg, Nicolaas A Bakker, Roman Hájek, Maria-Victoria Mateos, Paul G Richardson, Pieter Sonneveld. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
The Lancet. Haematology.
2022 Feb; 9(2):e98-e110. doi:
10.1016/s2352-3026(21)00381-1. [PMID: 35032434] - Takafumi Ide, Mayu Osawa, Kinjal Sanghavi, Heather E Vezina. Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma.
Cancer chemotherapy and pharmacology.
2022 01; 89(1):129-140. doi:
10.1007/s00280-021-04365-4. [PMID: 34825942] - Maria Francesca Palmas, Anna Ena, Chiara Burgaletto, Maria Antonietta Casu, Giuseppina Cantarella, Ezio Carboni, Michela Etzi, Alfonso De Simone, Giuliana Fusco, Maria Cristina Cardia, Francesco Lai, Luca Picci, David Tweedie, Michael T Scerba, Valentina Coroneo, Renato Bernardini, Nigel H Greig, Augusta Pisanu, Anna R Carta. Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.
2022 01; 19(1):305-324. doi:
10.1007/s13311-022-01182-2. [PMID: 35072912] - Paul G Richardson, Simon J Harrison, Sara Bringhen, Fredrik Schjesvold, Kwee Yong, Frank Campana, Solenn Le-Guennec, Sandrine Macé, Meletios A Dimopoulos. Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study.
Future oncology (London, England).
2021 Dec; 17(34):4797-4812. doi:
10.2217/fon-2021-0568. [PMID: 34521277] - Philippe Moreau, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Kwee Yong, Marcelo Capra, Thierry Facon, Roman Hajek, Ivan Špička, Ross Baker, Kihyun Kim, Gracia Martinez, Chang-Ki Min, Ludek Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, Marie-Laure Risse, Gaelle Asset, Sandrine Macé, Thomas Martin. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Lancet (London, England).
2021 06; 397(10292):2361-2371. doi:
10.1016/s0140-6736(21)00592-4. [PMID: 34097854] - Bernard Regidor, Regina Swift, Benjamin Eades, Marsiye Emamy-Sadr, Fadi Tarhini, Tanya M Spektor, James R Berenson. Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study.
Annals of hematology.
2021 Apr; 100(4):1079-1085. doi:
10.1007/s00277-020-04351-5. [PMID: 33237342] - Ahmadreza Arbab, Veronique Saada, Sophie Cotteret, Christophe Marzac, David Ghez. Plasma cell dedifferentiation in refractory multiple myeloma.
British journal of haematology.
2021 04; 193(2):212. doi:
10.1111/bjh.17244. [PMID: 33772753] - Anum Qureshi, Ji Hyun Rhee. Hyponatraemia due to hypothyroidism: a rare side effect from pomalidomide.
BMJ case reports.
2021 Mar; 14(3):. doi:
10.1136/bcr-2020-240168. [PMID: 33653858] - Isin Yagmur Comba, Anthony Chahin, Hiffsa Taj, Allison Carilli. Pomalidomide and dexamethasone in myelomatous pleural effusion.
BMJ case reports.
2020 Dec; 13(12):. doi:
10.1136/bcr-2020-235899. [PMID: 33303498] - Jean-Baptiste Fau, Raouf El-Cheikh, Claire Brillac, Kimiko Koiwai, Nathalie Mace, Frank Campana, Dorothee Semiond, Laurent Nguyen. Drug-Disease Interaction and Time-Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients.
CPT: pharmacometrics & systems pharmacology.
2020 11; 9(11):649-658. doi:
10.1002/psp4.12561. [PMID: 33021075] - Rajshekhar Chakraborty, Suzanne Lentzsch. Emerging drugs for the treatment of light chain amyloidosis.
Expert opinion on emerging drugs.
2020 09; 25(3):299-317. doi:
10.1080/14728214.2020.1803829. [PMID: 32731778] - Go Woon Kim, Jung Yoo, Hye-Rim Won, Soo-Keun Yeon, Sang Woo Lee, Dong Hoon Lee, Yu Hyun Jeon, So Hee Kwon. A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma.
Leukemia research.
2020 08; 95(?):106398. doi:
10.1016/j.leukres.2020.106398. [PMID: 32512378] - Z Aydoğmuş, E M Yılmaz, G Yildiz. A simple and rapid spectrofluorometric determination of pomalidomide in spiked plasma and urine. Application to degradation studies.
Luminescence : the journal of biological and chemical luminescence.
2020 Jun; 35(4):466-477. doi:
10.1002/bio.3748. [PMID: 31851418] - Masao Hagihara, Shiro Ide, Shin Ohara, Tomoyuki Uchida, Morihiro Inoue, Jian Hua. [Pomalidomide/cyclophosphamide/dexamethasone combination therapy for relapsed/refractory multiple myeloma accompanied by extramedullary lesions].
[Rinsho ketsueki] The Japanese journal of clinical hematology.
2020; 61(1):20-26. doi:
10.11406/rinketsu.61.20. [PMID: 32023597] - Ameet K Mishra, David Dingli. Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells.
Leukemia.
2019 11; 33(11):2695-2709. doi:
10.1038/s41375-019-0470-4. [PMID: 30988378] - Justin R Arnall, Saad Z Usmani, Hawawu Adamu, Joseph Mishkin, Manisha Bhutani. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2019 Jun; 25(4):1021-1025. doi:
10.1177/1078155218815305. [PMID: 30477388] - Diurbis Velasco-Álvarez, Luis Gorospe-Sarasúa, Sara Fra-Fernández, María Jesús Blanchard. Extramedullary Multiple Myeloma With Pleural Involvement: A Rare Clinical Entity.
Archivos de bronconeumologia.
2019 Jun; 55(6):333-334. doi:
10.1016/j.arbres.2018.08.011. [PMID: 30360996] - Raquel Jiménez-Segura, Miquel Granell, Mercè Gironella, Eugenia Abella, Antoni García-Guiñón, Albert Oriol, Elena Cabezudo, Victoria Clapés, Joan Alfons Soler, Lourdes Escoda, Jordi López-Pardo, Carlos Fernández de Larrea, Maria Teresa Cibeira, Natalia Tovar, Ignacio Isola, Joan Bladé, Laura Rosiñol. Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma.
European journal of haematology.
2019 May; 102(5):389-394. doi:
10.1111/ejh.13217. [PMID: 30719772] - Shunichiro Yasuda, Yuho Najima, Tatsuya Konishi, Yuta Yamada, Toshiaki Takezaki, Shuhei Kurosawa, Masahiro Sakaguchi, Kaito Harada, Kosuke Yoshioka, Aiko Igarashi, Kyoko Inamoto, Takashi Toya, Takeshi Kobayashi, Noriko Doki, Kazuhiko Kakihana, Hisashi Sakamaki, Noritaka Sekiya, Kazuteru Ohashi. Disseminated adenovirus infection in a patient with relapsed refractory multiple myeloma undergoing autologous stem cell transplantation and pomalidomide/dexamethasone as salvage regimens.
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
2019 May; 25(5):371-375. doi:
10.1016/j.jiac.2018.11.011. [PMID: 30642772] - Benjamin G Barwick, Paola Neri, Nizar J Bahlis, Ajay K Nooka, Madhav V Dhodapkar, David L Jaye, Craig C Hofmeister, Jonathan L Kaufman, Vikas A Gupta, Daniel Auclair, Jonathan J Keats, Sagar Lonial, Paula M Vertino, Lawrence H Boise. Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.
Nature communications.
2019 04; 10(1):1911. doi:
10.1038/s41467-019-09555-6. [PMID: 31015454] - Yan Li, Xiaomin Wang, Liangang Liu, Chengyue Zhang, Diana Gomez, Josephine Reyes, Maria Palmisano, Simon Zhou. An Open-Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics.
Clinical pharmacology in drug development.
2019 04; 8(3):346-354. doi:
10.1002/cpdd.470. [PMID: 29746728] - Ashleigh P Scott, Peter Mollee. Pomalidomide - Author Reply.
Leukemia & lymphoma.
2019 04; 60(4):1105. doi:
10.1080/10428194.2018.1516884. [PMID: 30277106] - Yan-Rou Tsai, David Tweedie, Ignacio Navas-Enamorado, Michael T Scerba, Cheng-Fu Chang, Jing-Huei Lai, John Chung-Che Wu, Yen-Hua Chen, Shuo-Jhen Kang, Barry J Hoffer, Rafael de Cabo, Nigel H Greig, Yung-Hsiao Chiang, Kai-Yun Chen. Pomalidomide Reduces Ischemic Brain Injury in Rodents.
Cell transplantation.
2019 04; 28(4):439-450. doi:
10.1177/0963689719850078. [PMID: 31094216] - Majid Ghaderi, Shahrbanoo Oryan, Namdar Yousofvand, Akram Eidi. Inhibition of Airway Contraction and Inflammation by Pomalidomide in a Male Wistar Rat Model of Ovalbumin-induced Asthma.
Iranian journal of allergy, asthma, and immunology.
2019 Apr; 18(2):209-217. doi:
10.18502/ijaai.v18i2.924. [PMID: 31066257] - Yan-Rou Tsai, Cheng-Fu Chang, Jing-Huei Lai, John Chung-Che Wu, Yen-Hua Chen, Shuo-Jhen Kang, Barry J Hoffer, David Tweedie, Weiming Luo, Nigel H Greig, Yung-Hsiao Chiang, Kai-Yun Chen. Pomalidomide Ameliorates H₂O₂-Induced Oxidative Stress Injury and Cell Death in Rat Primary Cortical Neuronal Cultures by Inducing Anti-Oxidative and Anti-Apoptosis Effects.
International journal of molecular sciences.
2018 Oct; 19(10):. doi:
10.3390/ijms19103252. [PMID: 30347766] - Yan Li, Liangang Liu, Xiaomin Wang, Chengyue Zhang, Josephine Reyes, Matthew Hoffmann, Maria Palmisano, Simon Zhou. In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects.
Journal of clinical pharmacology.
2018 10; 58(10):1295-1304. doi:
10.1002/jcph.1145. [PMID: 29762875] - Ross Tomlinson. Multiple myeloma: Updated approach to management in 2018.
Australian journal of general practice.
2018 08; 47(8):526-529. doi:
10.31128/ajgp-01-18-4473. [PMID: 30114882] - Joan Bladé, Laura Rosiñol, María Teresa Cibeira, Carlos Fernández de Larrea. Treatment of Relapsed Myeloma in a Patient With Renal Insufficiency.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2018 07; 36(20):2012-2016. doi:
10.1200/jco.2017.77.6419. [PMID: 29851545] - Nisha S Joseph, Jonathan L Kaufman. Novel Approaches for the Management of AL Amyloidosis.
Current hematologic malignancy reports.
2018 06; 13(3):212-219. doi:
10.1007/s11899-018-0450-1. [PMID: 29951831] - Yuka Aoki, Toshiaki Hayashi, Hiroshi Ikeda, Tadao Ishida. [Successful treatment with thalidomide-combined therapy in an amyloidosis-complicated multiple myeloma patient refractory to bortezomib, lenalidomide, and pomalidomide].
[Rinsho ketsueki] The Japanese journal of clinical hematology.
2018 ; 59(3):275-280. doi:
10.11406/rinketsu.59.275. [PMID: 29618684] - Yasuo Aota, Akihiko Gotoh, Yuko Okuda, Tadahiro Honda, Naoki Watanabe, Jun Ando, Norio Komatsu. [Recurrent amylase-producing multiple myeloma responding to pomalidomide and carfilzomib-containing therapies].
[Rinsho ketsueki] The Japanese journal of clinical hematology.
2018 ; 59(7):865-871. doi:
10.11406/rinketsu.59.865. [PMID: 30078795] - Makiko Shimizu, Hiroshi Suemizu, Marina Mitsui, Norio Shibata, F Peter Guengerich, Hiroshi Yamazaki. Metabolic profiles of pomalidomide in human plasma simulated with pharmacokinetic data in control and humanized-liver mice.
Xenobiotica; the fate of foreign compounds in biological systems.
2017 Oct; 47(10):844-848. doi:
10.1080/00498254.2016.1247218. [PMID: 27852146] - Joshua Richter, Noa Biran, Narjust Duma, David H Vesole, David Siegel. Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series.
Hematological oncology.
2017 Jun; 35(2):246-251. doi:
10.1002/hon.2290. [PMID: 27018162] - Kim Dao, Haithem Chtioui, Yimin Lu, Cody J Peer, William D Figg, Menno Pruijm, Thierry Buclin, Sébastien Kissling. Pharmacokinetics of Pomalidomide in a Patient Receiving Hemodialysis Using a High-Cutoff Filter.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2017 Apr; 69(4):553-554. doi:
10.1053/j.ajkd.2016.10.026. [PMID: 28063733] - Sarah A Holstein, Philip L McCarthy. Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.
Drugs.
2017 Apr; 77(5):505-520. doi:
10.1007/s40265-017-0689-1. [PMID: 28205024] - Nicola Maciocia, Andrew Melville, Simon Cheesman, Faye Sharpley, Karthik Ramasamy, Matthew Streetly, Matthew Jenner, Reuben Benjamin, Steve Schey, Paul Maciocia, Rakesh Popat, Shirley D'sa, Ali Rismani, Aviva Cerner, Kwee Yong, Neil Rabin. Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.
British journal of haematology.
2017 03; 176(6):908-917. doi:
10.1111/bjh.14547. [PMID: 28211054] - Rimda Wanchoo, Ala Abudayyeh, Mona Doshi, Amaka Edeani, Ilya G Glezerman, Divya Monga, Mitchell Rosner, Kenar D Jhaveri. Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.
Clinical journal of the American Society of Nephrology : CJASN.
2017 01; 12(1):176-189. doi:
10.2215/cjn.06100616. [PMID: 27654928] - Shahzad Raza, Rachael A Safyan, Suzanne Lentzsch. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
Current cancer drug targets.
2017; 17(9):846-857. doi:
10.2174/1568009617666170214104426. [PMID: 28201976] - Maria Gavriatopoulou, Evangelos Terpos, Efstathios Kastritis, Meletios A Dimopoulos. Current treatments for renal failure due to multiple myeloma.
Expert opinion on pharmacotherapy.
2016 Nov; 17(16):2165-2177. doi:
10.1080/14656566.2016.1236915. [PMID: 27646819] - Kaoru Torigoe, Naoki Nakayama, Hiroyuki Achiwa. Pomalidomide (Pomalyst(®) capsule 1 mg/2 mg/3 mg/4 mg): pharmacokinetics, pharmacodynamics and clinical study outcome.
Nihon yakurigaku zasshi. Folia pharmacologica Japonica.
2016 09; 148(3):154-61. doi:
10.1254/fpj.148.154. [PMID: 27581964] - Katja C Weisel, Meletios A Dimopoulos, Philippe Moreau, Martha Q Lacy, Kevin W Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Anne Banos, Albert Oriol, Adrian Alegre, Christine Chen, Michele Cavo, Laurent Garderet, Valentina Ivanova, Joaquin Martinez-Lopez, Stefan Knop, Xin Yu, Kevin Hong, Lars Sternas, Christian Jacques, Mohamed H Zaki, Jesus San Miguel. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.
Haematologica.
2016 07; 101(7):872-8. doi:
10.3324/haematol.2015.137083. [PMID: 27081177] - Pieter Sonneveld, Annemiek Broijl. Treatment of relapsed and refractory multiple myeloma.
Haematologica.
2016 Apr; 101(4):396-406. doi:
10.3324/haematol.2015.129189. [PMID: 27033237] - Phylicia Baird, Sam Leung, Huy Hoang, Olawumi Babalola, Craig E Devoe, Rimda Wanchoo, Kenar D Jhaveri. A case of acute kidney injury from crystal nephropathy secondary to pomalidomide and levofloxacin use.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2016 Apr; 22(2):357-60. doi:
10.1177/1078155214568581. [PMID: 25591868] - Jonghoon Park, Eok Park, Cheol-Kyu Jung, Seung-Wan Kang, Byung Gyu Kim, Youngjoo Jung, Tae Hun Kim, Ji-Young Lim, Sung-Eun Lee, Chang-Ki Min, Kwang-Ai Won. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
BMC cancer.
2016 Mar; 16(?):247. doi:
10.1186/s12885-016-2285-2. [PMID: 27012957] - T Jelinek, Z Kufova, R Hajek. Immunomodulatory drugs in AL amyloidosis.
Critical reviews in oncology/hematology.
2016 Mar; 99(?):249-60. doi:
10.1016/j.critrevonc.2016.01.004. [PMID: 26806146] - H Jiang, C Acharya, G An, M Zhong, X Feng, L Wang, N Dasilva, Z Song, G Yang, F Adrian, L Qiu, P Richardson, N C Munshi, Y-T Tai, K C Anderson. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide.
Leukemia.
2016 Feb; 30(2):399-408. doi:
10.1038/leu.2015.240. [PMID: 26338273] - Giuseppe Mele, Maria Rosaria Coppi, Gianluca Guaragna, Alessandro Spina, Angela Melpignano. Response to pomalidomide plus fixed low-dose dexamethasone in a case of secondary plasma cell leukaemia.
Leukemia research.
2016 Jan; 40(?):30-2. doi:
10.1016/j.leukres.2015.11.009. [PMID: 26626205] - Xue Song, Ze Cong, Kathleen Wilson. Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States.
Current medical research and opinion.
2016; 32(1):95-103. doi:
10.1185/03007995.2015.1105202. [PMID: 26488820] - Michiko Kida, Masako Hirao, Hiromitsu Iizuka, Akira Hangaishi, Kensuke Usuki. Efficacy of pomalidomide in a multiple myeloma patient requiring hemodialysis.
[Rinsho ketsueki] The Japanese journal of clinical hematology.
2016; 57(11):2339-2344. doi:
10.11406/rinketsu.57.2339. [PMID: 27941283] - C C Bjorklund, L Lu, J Kang, P R Hagner, C G Havens, M Amatangelo, M Wang, Y Ren, S Couto, M Breider, Y Ning, A K Gandhi, T O Daniel, R Chopra, A Klippel, A G Thakurta. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Blood cancer journal.
2015 Oct; 5(?):e354. doi:
10.1038/bcj.2015.66. [PMID: 26430725] - Muzaffar Iqbal, Essam Ezzeldin, Khalid A Al-Rashood, Faiyaz Shakeel. A validated UPLC-MS/MS assay using negative ionization mode for high-throughput determination of pomalidomide in rat plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2015 Mar; 983-984(?):76-82. doi:
10.1016/j.jchromb.2014.12.036. [PMID: 25621435] - Grzegorz Raszewski, Marta Kinga Lemieszek, Krzysztof Łukawski, Małgorzata Juszczak, Wojciech Rzeski. Chlorpyrifos and cypermethrin induce apoptosis in human neuroblastoma cell line SH-SY5Y.
Basic & clinical pharmacology & toxicology.
2015 Feb; 116(2):158-67. doi:
10.1111/bcpt.12285. [PMID: 24975276] - Meletios A Dimopoulos, Paul G Richardson, Philippe Moreau, Kenneth C Anderson. Current treatment landscape for relapsed and/or refractory multiple myeloma.
Nature reviews. Clinical oncology.
2015 Jan; 12(1):42-54. doi:
10.1038/nrclinonc.2014.200. [PMID: 25421279] - Brenda De Keersmaecker, Karel Fostier, Jurgen Corthals, Sofie Wilgenhof, Carlo Heirman, Joeri L Aerts, Kris Thielemans, Rik Schots. Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation.
Cancer immunology, immunotherapy : CII.
2014 Oct; 63(10):1023-36. doi:
10.1007/s00262-014-1571-6. [PMID: 24947180] - Bryant B Summers, Sabrina W Cole, Jacqueline L Olin. Pomalidomide for the management of refractory multiple myeloma.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
2014 Sep; 71(17):1443-8. doi:
10.2146/ajhp130752. [PMID: 25147167] - Kaitlin N Highsmith, Sheree E Chen, Sandy Horowitz. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
Pharmacotherapy.
2014 Sep; 34(9):927-40. doi:
10.1002/phar.1463. [PMID: 25044413] - Shandiz Shahbazi, Cody J Peer, Mark N Polizzotto, Thomas S Uldrick, Jeffrey Roth, Kathleen M Wyvill, Karen Aleman, Jerome B Zeldis, Robert Yarchoan, William D Figg. A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses.
Journal of pharmaceutical and biomedical analysis.
2014 Apr; 92(?):63-8. doi:
10.1016/j.jpba.2014.01.001. [PMID: 24486861] - Yao Jiang, Jiang Wang, Darlene M Rozewski, Shamalatha Kolli, Chia-Hsien Wu, Ching-Shih Chen, Xiaoxia Yang, Craig C Hofmeister, John C Byrd, Amy J Johnson, Mitch A Phelps. Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue.
Journal of pharmaceutical and biomedical analysis.
2014 Jan; 88(?):262-8. doi:
10.1016/j.jpba.2013.08.036. [PMID: 24095801] - J Gras. Pomalidomide for patients with multiple myeloma.
Drugs of today (Barcelona, Spain : 1998).
2013 Sep; 49(9):555-62. doi:
10.1358/dot.2013.49.9.2017031. [PMID: 24086951] - Arleigh R McCurdy, Martha Q Lacy. Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist.
Therapeutic advances in hematology.
2013 Jun; 4(3):211-6. doi:
10.1177/2040620713480155. [PMID: 23730498] - Paul G Richardson, David Siegel, Rachid Baz, Susan L Kelley, Nikhil C Munshi, Jacob Laubach, Daniel Sullivan, Melissa Alsina, Robert Schlossman, Irene M Ghobrial, Deborah Doss, Nora Loughney, Laura McBride, Elizabeth Bilotti, Palka Anand, Lisa Nardelli, Sandra Wear, Gail Larkins, Min Chen, Mohamad H Zaki, Christian Jacques, Kenneth C Anderson. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
Blood.
2013 Mar; 121(11):1961-7. doi:
10.1182/blood-2012-08-450742. [PMID: 23243282] - Matthew Hoffmann, Claudia Kasserra, Josephine Reyes, Peter Schafer, Jolanta Kosek, Lori Capone, Anastasia Parton, Heasook Kim-Kang, Sekhar Surapaneni, Gondi Kumar. Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration.
Cancer chemotherapy and pharmacology.
2013 Feb; 71(2):489-501. doi:
10.1007/s00280-012-2040-6. [PMID: 23203815] - Roberto Castelli, Antonino Cannavò, Fabio Conforti, Giovanni Grava, Agostino Cortelezzi. Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice.
Immunopharmacology and immunotoxicology.
2012 Oct; 34(5):740-53. doi:
10.3109/08923973.2012.658921. [PMID: 22401643] - Angela Dispenzieri, Francis Buadi, Kristina Laumann, Betsy LaPlant, Suzanne R Hayman, Shaji K Kumar, David Dingli, Steven R Zeldenrust, Joseph R Mikhael, Robert Hall, S Vincent Rajkumar, Craig Reeder, Rafael Fonseca, P Lief Bergsagel, A Keith Stewart, Vivek Roy, Thomas E Witzig, John A Lust, Stephen J Russell, Morie A Gertz, Martha Q Lacy. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.
Blood.
2012 Jun; 119(23):5397-404. doi:
10.1182/blood-2012-02-413161. [PMID: 22493299] - Rubén Niesvizky. Novel therapies in monoclonal gammopathies.
Hematology (Amsterdam, Netherlands).
2012 Apr; 17 Suppl 1(?):S121-4. doi:
10.1179/102453312x13336169156294. [PMID: 22507798] - Hideaki Kawada, Naomichi Arima. [Update on treatment of multiple myeloma: including myeloma kidney and molecular targeting drugs].
Nihon Jinzo Gakkai shi.
2012; 54(5):586-92. doi:
NULL. [PMID: 22991837] - Martha Q Lacy. New immunomodulatory drugs in myeloma.
Current hematologic malignancy reports.
2011 Jun; 6(2):120-5. doi:
10.1007/s11899-011-0077-y. [PMID: 21327565] - Ming Jen Tsai, Chinpiao Chen, Sung-Ho Chen, Yen Ta Huang, Ted H Chiu. Pomalidomide suppresses cerulein-induced acute pancreatitis in mice.
Journal of gastroenterology.
2011 Jun; 46(6):822-33. doi:
10.1007/s00535-011-0394-x. [PMID: 21437599] - Animesh Pardanani, Kebede Begna, Christy Finke, Terra Lasho, Ayalew Tefferi. Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis.
American journal of hematology.
2011 Apr; 86(4):343-5. doi:
10.1002/ajh.21972. [PMID: 21442636] - Mary B Kelly, Teresa Meenaghan, Maura Dowling. Myeloma: making sense of a complex blood cancer.
British journal of nursing (Mark Allen Publishing).
2010 Dec; 19(22):1415-21. doi:
10.12968/bjon.2010.19.22.1415. [PMID: 21139523] - Matthew Streetly, Beverley J Hunt, Kiran Parmar, Richard Jones, Jerome Zeldis, Steve Schey. Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis.
European journal of haematology.
2005 Apr; 74(4):293-6. doi:
10.1111/j.1600-0609.2004.00393.x. [PMID: 15777340] - S A Schey, P Fields, J B Bartlett, I A Clarke, G Ashan, R D Knight, M Streetly, A G Dalgleish. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2004 Aug; 22(16):3269-76. doi:
10.1200/jco.2004.10.052. [PMID: 15249589] - J Blake Bartlett, Keith Dredge, Angus G Dalgleish. The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Nature reviews. Cancer.
2004 04; 4(4):314-22. doi:
10.1038/nrc1323. [PMID: 15057291] - Steve K Teo, Yong Chen, George W Muller, Roger S Chen, Steve D Thomas, David I Stirling, Reddy S Chandula. Chiral inversion of the second generation IMiD CC-4047 (ACTIMID ) in human plasma and phosphate-buffered saline.
Chirality.
2003 May; 15(4):348-51. doi:
10.1002/chir.10221. [PMID: 12666243] - J B Marriott, I A Clarke, K Dredge, G Muller, D Stirling, A G Dalgleish. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.
Clinical and experimental immunology.
2002 Oct; 130(1):75-84. doi:
10.1046/j.1365-2249.2002.01954.x. [PMID: 12296856] - H J Hilderson, M J De Wolf, A R Lagrou, W S Dierick. Subcellular structure of bovine thyroid gland. A study on bovine thyroid membranes by buoyant-density-gradient centrifugation in a B-XIV zonal rotor.
The Biochemical journal.
1975 Dec; 152(3):601-7. doi:
10.1042/bj1520601. [PMID: 5997]